文献速递类风湿关节炎

血清代谢组学分析鉴定预测类风湿关节炎生物制剂治疗反应的生物标志物

Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究采用毛细管电泳-飞行时间质谱(CE-TOFMS)分析43例中高疾病活动度RA患者生物制剂治疗前的血清代谢组学特征,以EULAR反应标准评估12周疗效。TNFi组26例中14例应答,ABT组17例中6例应答,鉴定出5个TNFi应答预测代谢物和3个ABT应答预测代谢物,多标志物ROC分析显示TNFi的AUC为0.941(灵敏度85.7%,特异度100%),ABT的AUC为0.985(灵敏度100%,特异度90.9%)。

要点

  • CE-TOFMS可鉴定RA患者血清代谢组学特征并筛选生物制剂应答预测标志物。
  • TNFi应答预测的多标志物模型AUC为0.941,灵敏度85.7%,特异度100%。
  • ABT应答预测的多标志物模型AUC为0.985,灵敏度100%,特异度90.9%。

核心结论

  • 通过代谢组学分析鉴定出的血清生物标志物对预测RA患者TNFi或ABT治疗反应具有较高能力。

研究设计与样本

  • 研究纳入43例中高疾病活动度RA患者,采集生物制剂治疗前血清,采用CE-TOFMS获取代谢组学图谱,治疗12周后按EULAR反应标准判定应答。

主要发现

  • TNFi组26例中14例应答,ABT组17例中6例应答。
  • CE-TOFMS分离的代谢物中196个被鉴定为已知物质。
  • 采用正交偏最小二乘判别分析鉴定出5个TNFi应答潜在预测代谢物和3个ABT应答潜在预测代谢物。

关键数值与推荐

  • TNFi多标志物ROC分析AUC为0.941,灵敏度85.7%,特异度100%。
  • ABT多标志物ROC分析AUC为0.985,灵敏度100%,特异度90.9%。

临床怎么用

  • 治疗前血清代谢组学标志物可能辅助筛选RA患者对TNFi或ABT的应答概率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Biologic treatment has recently revolutionized the management of RA. Despite this success, ∼30-40% of the patients undergoing biologic treatment respond insufficiently. The aim of this study was to identify several specific reliable metabolites for predicting the response of RA patients to TNF-α inhibitors (TNFi) and abatacept (ABT), using capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS). METHODS: We collected serum from RA patients with moderate or high disease activity prior to biologic treatment, and obtained the serum metabolomic profiles of these samples using CE-TOFMS. The patients' response was determined 12 weeks after starting biologic treatment, according to the EULAR response criteria. We compared the metabolites between the response and non-response patient groups and analysed their discriminative ability. RESULTS: Among 43 total patients, 14 of 26 patients in the TNFi group and 6 of 17 patients in the ABT group responded to the biologic treatment. Of the metabolites separated by CE-TOFMS, 196 were identified as known substances. Using an orthogonal partial least-squares discriminant analysis, we identified five metabolites as potential predictors of TNFi responders and three as predictors of ABT responders. Receiver operating characteristic analyses for multiple biomarkers revealed an area under the curve (AUC) of 0.941, with a sensitivity of 85.7% and specificity of 100% for TNFi, and an AUC of 0.985, with a sensitivity of 100% and specificity of 90.9% for ABT. CONCLUSION: By metabolomic analysis, we identified serum biomarkers that have a high ability to predict the response of RA patients to TNFi or ABT treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takahashi S, Saegusa J, Onishi A, et al. Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients. Rheumatology (Oxford). 2019. PMID: 31143951. doi:10.1093/rheumatology/kez199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。